• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Mineralys Therapeutics (MLYS) Undervalued After New Phase 3 Lorundrostat Data?

    Simply Wall St·10/11/2026 01:37:10
    Listen to the news

    Mineralys Therapeutics (MLYS) drew fresh attention after new data from its Phase 3 Launch-HTN trial showed 46% of lorundrostat patients hit guideline blood pressure targets at 12 weeks, with supportive Phase 2 Explore-OSA results.

    The latest clinical readouts land after a choppy period for Mineralys Therapeutics shares, with the stock closing at US$23.37 and a 1 day share price return of 4.42% following the Launch HTN update.

    Over the past month the share price return declined 23.38%, and the year to date move is down 34.56%, even though the 3 year total shareholder return is a strong gain of about 1.6x.

    That mix of short term share price weakness and a steep 1 year total shareholder return decline of 44.57% suggests investors have been reassessing both the opportunity and the risks around lorundrostat, and this new Phase 3 and Phase 2 data now feeds directly into that debate.

    Scan 31 resilient stocks with low risk scores to see how other resilient healthcare stocks with stronger risk profiles compare to the clinical progress story unfolding at Mineralys Therapeutics.

    The recent slide in Mineralys Therapeutics despite fresh lorundrostat data raises a simple question. Are investors marking down the underlying business or just resetting sentiment around a single asset story?

    Most Popular Narrative: 52% Undervalued

    On the most followed view, Mineralys Therapeutics screens as deeply discounted, with a fair value of $48.50 against a last close of $23.37. That gap is being pinned squarely on how lorundrostat could change the earnings profile if the late stage plan holds together.

    Mineralys Therapeutics is a biopharmaceutical company focused on developing lorundrostat, an aldosterone synthase inhibitor, for patients with uncontrolled and resistant hypertension and related cardiorenal conditions.

    Progress toward an NDA filing for lorundrostat in uncontrolled and resistant hypertension, supported by multiple Phase III and proof of concept trials, positions the company to potentially transition from a pure R&D story toward a revenue generating profile, which could materially affect future revenue and earnings visibility.

    See why 4 investors see Mineralys Therapeutics as 52% undervalued.

    Result: Fair Value of $48.50 (UNDERVALUED)

    Still, the whole Mineralys Therapeutics story hinges on lorundrostat clearing regulatory hurdles and on future funding needs not forcing heavier-than-expected dilution.

    Find out about the key risks to this Mineralys Therapeutics narrative.

    Next Steps

    There are mixed signals on Mineralys Therapeutics so far. If you want to form your own perspective before sentiment changes again, start with the 2 key rewards and 1 important warning sign.

    Looking for more investment ideas beyond Mineralys Therapeutics?

    If Mineralys Therapeutics is on your radar, do not stop there. The strongest portfolios usually come from comparing multiple opportunities side by side.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.